Previous 10 | Next 10 |
Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $0.17 for Q3 2023
2023-11-08 13:37:25 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: The Right Play Now Ironwood: Pipeline Progresses As FDA Approves LINZESS JMP starts Ironwood at market outperform, cites potential of GLP-2 drug Seeking Alpha’s Quant Rat...
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada)...
– Data reinforce the impact of linaclotide on symptoms of IBS-C and CIC – – Additional studies highlight the burden of these disorders on patients – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, present...
– Data show approximately 50% reduction of parenteral support (PS) volume – – 100% of patients were clinical responders – – 78% of patients achieved one or more days off PS – – Results support apraglutide as a potentiall...
– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of linaclotide as the only FDA-approved prescription therapy for this patient pop...
2023-09-28 12:52:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals Historical ear...
2023-09-19 11:18:41 ET More on Ironwood Pharmaceuticals Ironwood: Pipeline Progresses As FDA Approves LINZESS Seeking Alpha's Quant Rating on Ironwood Pharmaceuticals Historical earnings data for Ironwood Pharmaceuticals Financial information for Ironwood Pha...
2023-08-08 11:26:07 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2023 Earnings Call Transcript August 08, 2023 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Sravan Emany - Chief Financial Office...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...